For investors
An opportunity to take part in the next chapter of cancer diagnostics.
DIASCI is a Brazilian deep tech combining electrochemical biosensing and AI — built on research, preliminary findings and an intellectual property strategy, and now seeking investors for its next milestones.
Market opportunity
The opportunity thesis
Oncology still needs accessible, less invasive ways to generate information for detection and follow-up. Technologies that turn biological signals into structured data may open new value chains in diagnostics.
- Convergence of biosensing, data and AI in health
- Demand for new detection and follow-up approaches in oncology
- Market size and sizing data to be presented with verifiable sources
How DIASCI may contribute
Technological differentiators
DIASCI integrates an electrochemical biosensor (DIONCO) with an AI analysis layer — two assets developed in-house that may be combined or licensed separately.
- Hardware and analytics developed as one platform
- Patent applications in Brazil (INPI) and via PCT — applications, not granted patents
- Participation in regulatory alternative-methods context (MCTI / RENAMA assessment)
Potential applications and expected benefits
Scalability and monetization paths
Potential applicationLicensing
Rights to use the technology in defined applications or territories.
Co-development
Joint programs with pharma, laboratories or technology companies.
Future digital applications
Possible AI-based features once the platform matures.
Scalability
Platform logic may extend to other biomarkers — still subject to validation.
Evidence and current stage
No valuation, round size or financial projection is published here. Development milestones are shared in direct conversations.
DIONCO biosensor
Technology in development.
Preliminary findings
Company-reported results that support further assessment.
Intellectual property
Patent applications filed.
Next milestones
Validation and development milestones to be detailed by DIASCI.
DIONCO and the AI platform are in development. Preliminary, company-reported findings support further assessment; clinical and regulatory validation is still required. No product is currently approved or commercially available.
Possible collaboration models
Exploratory possibilities only. Any model depends on mutual interest, due diligence and formal agreements.
Investment
Dialogue with investors who share the long-term view of a health deep tech.
Technology licensing
A future revenue path built on the intellectual property strategy.
Co-development
Partnerships that may accelerate validation and de-risk milestones.
Request a meeting
Request a Meeting with DIASCI
Request a conversation with the founders. Financial terms, if any, are discussed only in direct dialogue and under appropriate confidentiality.